Premier Pharmacy Recalls Neostigmine Syringes Due to Sterility Risk
Premier Pharmacy Labs recalls 600 syringes of Neostigmine Methylsulfate due to potential microbial contamination from packaging interaction.
Stop using this now
Lack of Assurance of Sterility:Microbial contamination was detected during routine testing of subsequent unreleased product lots due to interaction between the product syringe and tamper evident container closure, which may result in the potential introduction of microorganisms into the products.
Contact the company
What happened, in plain English
Premier Pharmacy Labs Inc is recalling 600 single-dose syringes of Neostigmine Methylsulfate (1 mg/mL) distributed nationwide. The recall was issued because routine testing detected microbial contamination in subsequent unreleased lots, caused by an interaction between the syringe and the tamper-evident container closure. This defect may allow microorganisms to enter the product. Read more at govinfonow.com/recall/40618-premier-pharmacy-recalls-neostigmine-syringes-due-to-sterility-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/40618-premier-pharmacy-recalls-neostigmine-syringes-due-to-sterility-risk · Updated October 11, 2026 · FDA enforcement record: FDA #D-0702-2018
Cite this page
“Premier Pharmacy Recalls Neostigmine Syringes Due to Sterility Risk.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/40618-premier-pharmacy-recalls-neostigmine-syringes-due-to-sterility-risk. Based on FDA recall #D-0702-2018 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0702-2018%22&limit=1).
Why it’s dangerous
The tamper-evident container closure interacts with the product syringe in a way that can introduce microorganisms into the sterile solution. Using contaminated injectable medication poses a serious risk of infection or other adverse health effects.
Who’s affected
Patients or healthcare providers who purchased or received Neostigmine Methylsulfate single-dose syringes from Premier Pharmacy Labs between distribution and the recall date. Individuals using this specific medication are at risk of exposure to microbial contamination.
How to tell if you have this one
Check for Neostigmine Methylsulfate (1 mg/mL) in 3mL single-dose syringes manufactured by Premier Pharmacy Labs. Verify if the lot number is NEO022218SVDS and the Best Use Date (BUD) is 8/21/2018. The National Drug Code (NDC) is 69623-234-14.
- Brand
Premier Pharmacy Labs- Category
Drug
All 4 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Terminated- Distribution
Nationwide in the USA
| Recall number | Product, codes & lots | Quantity |
|---|---|---|
| D-0699-2018 | Morphine Sulfate 2 mg/mL PF Injection. 1 mL in a 3ml Sterile Single-Dose Syringe. 8265 Commerical Way Weeki Wachee, FL 34613. NDC 69623-129-10; Lots: MOR030518IJDSA, MOR030518IJDSB, MOR030518IJDSC, MOR030518IJDSD, MOR030518IJDSE BUD: 06/03/2018; | 4555 syringes |
| D-0700-2018 | Morphine Sulfate 4 mg/mL PF Injection. 1 mL in a 3ml Sterile Single-Dose Syringe. 8265 Commerical Way Weeki Wachee, FL 34613. NDC 69623-127-10; Lots: MOR022318NWDSA, MOR022318NWDSB, MOR022318NWDSC, MOR022318NWDSD, MOR022318NWDSE BUD: 05/24/2018 | 4192 syringes |
| D-0701-2018 | Hydromorphone HCl 1 mg/mL PF INJ. 1mL in a 3mL Sterile Single-Dose Syringe. 8265 Commercial Way Weeki Wachee, FL 34613 NDC 69623-249-10; Lots: HYD030118IJDSA, HYD030118IJDSB, HYD030118IJDSD, HYD030118IJDSE BUD: 05/30/2018 | 3570 syringes |
| D-0702-2018 | NEOstigmine Methylsulfate (1 mg/mL) 3mg per 3mL. 3mL Single Dose Syringe. Premier Pharmacy Labs. 8265 Commercial Way Weeki Wachee, FL 34613 NDC 69623-234-14.; Lot: NEO022218SVDS BUD: 8/21/2018 | 600 syringes |
What to do — step by step
Stop Using the Product
Do not use any syringes matching the recalled lot number NEO022218SVDS due to sterility concerns.
Contact Your Provider
Reach out to your healthcare provider or pharmacist immediately to discuss alternative treatment options.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 2.4 years after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0702-2018 (April 11, 2018) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0702-2018 to see it in context.
- Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.